Drug Trial Radar · NCT02840279
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
Last checked: Nov 19, 2026Latest source record: Jan 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Jun 2016
Primary completion
Nov 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Tetra Discovery PartnersIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly male and female subjects and to provide a preliminary assessment of the cognitive effects of BPN14770 in healthy elderly subjects.
Conditions
- Alzheimer's Disease
Interventions
BPN14770Drug
BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jasper Clinic
Kalamazoo, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.